esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
Published 4 years ago • 2.3K plays • Length 2:39Download video MP4
Download video MP3
Similar videos
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
2:35
esmo 2020 highlights on 1st line durvalumab and tremelimumab for mpdac: the pa.7 study
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
3:04
esmo 2020 highlights on durability of clinical benefit and biomarkers with amg510 in nsclc
-
3:43
lorlatinib takes crown in head-to-head comparison with crizotinib | benjamin solomon
-
5:07
esmo 2020 expert video report on 1st line ici for gastro oesophageal cancer
-
5:28
crown study: lorlatinib vs crizotinib in 1l nsclc
-
1:02:24
esmo 2020 lung cancer highlights
-
2:27
esmo 2020 highlights on neoadjuvant ici in early tnbc: the impassion031 study
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
1:06
lung cancer highlights from esmo 2022
-
2:01
dr. christine lovly discusses with #oncoalert: the #crown study presented at #esmo20 (lung cancer)
-
2:26
esmo 2020 highlights on alpelisib plus fulvestrant for hr /her2– abc: the solar-1 study
-
13:06
challenges in first line alk positive nsclc management and emerging data on alk tkis in alk posi...
-
4:11
crown: biomarkers for lorlatinib response in patients with alk nsclc
-
35:16
highlights from esmo 2020
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
2:02
crown update: results of an asian subgroup analysis
-
1:27
genitourinary cancer highlights at esmo 2022